INTRODUCTION: Historically, female sterilization (FS) has been disproportionately concentrated among racial minorities and women with lower education and income. Given increasing popularity of long-acting reversible contraception (LARC), we examined changing socio-demographic patterns of FS and LARC usage. METHODS: We used data files from the National Survey of Family Growth 2006-2010 (earlier) and 2015-2017 (later) survey waves. We analyzed all women of reproductive age not seeking pregnancy, with a sub-analysis of FS and LARC, and extracted socio-demographic information. RESULTS: We included 11,073 respondents. From the earlier to later cohort, the prevalence of LARC increased 3-fold (7% to 20%), while FS dropped (25% to 22%). In our sub-analysis comparing LARC vs FS users (n=3918), the adjusted likelihood of LARC use was greater in the later cohort (OR 2.3 [1.6, 3.4]). When comparing LARC to FS in both cohorts, there were non-significant trends of reduced LARC use in black women (OR 0.51 [0.3, 1.1]), while Hispanic women emerged as more likely to use LARCs in the later cohort (OR 1.5 [0.9, 2.7]). Overall, the most significant predictors of LARC use in the later cohort remained younger age (>35), higher income ($75,000), and more education (OR 3.6 [1.9, 6.6], 5.3 [1.8, 15.9], and 4.5 [2.1, 9.7], respectively). Living in a metropolitan area emerged as a new predictor of LARC use over FS in the later cohort (OR 3.0 [1.3, 7.3]). CONCLUSION: Although LARC use increased and FS decreased, the most significant predictors of LARC over FS include higher income, more education and metropolitan residence, suggesting inequities in access.
Introduction: Screening for asymptomatic PAD (aPAD) with the ankle-brachial index (ABI) test may reduce mortality and disease progression by identifying individuals who may benefit from early initiation of cardiovascular (CV) risk reduction therapies. Methods: Using a Markov model, we evaluated the cost-effectiveness of initiating medical therapy (e.g. statin & ACE-inhibitor) after a positive ABI screen in adults 65-years old. We modeled progression to symptomatic PAD (sPAD) and CV mortality with and without screening evaluating quality adjust life years (QALY). Cost of the ABI test, physician visit, new medication, and surgery for sPAD were calculated. Our baseline model estimated 96% of patients already eligible for medical therapy given the similar risk factor profiles of aPAD and CV disease. Repeated screening was considered given the imperfect screening test, development of disease with age, and opportunity to re-initiate therapy given limited medication compliance. Variables with uncertainty underwent a tornado analysis to determine variables with large effects. Results: Our model found an incremental cost of $367 and incremental QALY of 0.0022 with one-time ABI screening resulting in an incremental cost-effectiveness ratio (ICER) of $169,025/QALY over a 35-year period. Removing the benefits of medication on CV mortality increases the ICER by 51%, and removing the benefits of medication on PAD progression increases the ICER by 16%. A tornado diagram shows variables affecting the ICER (Figure). Screening high-risk populations, such as tobacco users where the prevalence of PAD may be 2.5x higher than the general population of 9%, decreases the ICER to $63,500/QALY. Conclusions: Our cost-effective analysis predicts that one-time ABI screening does not meet generally accepted thresholds for cost effectiveness. Disease prevalence and medication adherence had the largest effects on the ICER and are important to consider in implementing ABI screening.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.